Edge Restenosis with Everolimus Eluting Stents: a few Predictors

Edge Restenosis with Everolimus Eluting StentsStent edge restenosis continues to be a weakness of drug eluting stents (DES). The aim of this study was to determine its predictors using optical coherence tomography (OCT).

 

The study retrospectively analyzed 319 patients receiving OCT immediately after everolimus eluting stent implantation (EES) looking into the immediate outcome, and follow up angiography at 9 and 12 months.

 

Binary angiographic stent edge restenosis was 10%. OCT more often showed lipidic plaque in patients with stent edge restenosis vs. those without it. (61% vs. 20%; p<0.001), as well as smaller minimal lumen area (4.13±2.61 vs. 5.58±2.46 mm2; p=0.001). Multivariable analysis confirmed these two variables are significant predictors of stent edge restenosis.

 

A lipidic arc of 185° (sensitivity: 71%; specificity: 72%; area under the curve: 0.761) and minimal lumen area of 4.10 mm2 (sensitivity: 67%; specificity: 77%; area under the curve: 0.787) were the ideal cutoff values to predict stent edge restenosis.

 

These results do not come as a surprise since it is well known that plaque in the distal or proximal stent edges and stent underexpansion are restenosis predictors.

 

Conclusion

OCT provides decisive information on optimal stent diameter and expansion to select the right stent length, which in turn will allow us to cover the whole plaque.

 

Original Title: Optical Coherence Tomography Predictors for Edge Restenosis after Everolimus-Eluting Stent Implantation.

Reference: Ino Y et al. Circ Cardiovasc Interv. 2016 Oct; 9(10).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...